Showing results (81-90 of 216) with videos related to

Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|September 20, 2024
Association between lorlatinib blood concentration and adverse events and clinical impact of dose modificationYukiko Igawa, Tatsuya Yoshida, Reiko Makihara, et al.
ESMO Open|December 19, 2018
Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutationsYuki Shinno, Yasushi Goto, Sho Watanabe, et al.
BMC Research Notes|December 20, 2015
Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinomaYosuke Tamura, Yutaka Fujiwara, Noboru Yamamoto, et al.
Cancer Science|June 9, 2016
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphismYutaka Fujiwara, Akinobu Hamada, Hidenori Mizugaki, et al.
Japanese Journal of Clinical Oncology|November 15, 2017
Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutionsSayaka Ohara, Shintaro Kanda, Hitomi Okuma, et al.
Japanese Journal of Clinical Oncology|August 7, 2014
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive casesHidenori Mizugaki, Yutaka Fujiwara, Noboru Yamamoto, et al.
Anticancer Research|May 27, 2026
The Association Between Longitudinal Changes in TRACP-5b and Bone Metastasis Progression During Osimertinib TherapyKeisuke Ikegami, Reiko Ando Makihara, Yuki Shinno, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapyYuki Katsuya, Hidehito Horinouchi, Tetsuhiko Asao, et al.
JTO Clinical and Research Reports|October 6, 2023
Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial TumorsHideki Ikeda, Joji Nagasaki, Daiki Shimizu, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2019
Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER studyYuki Katsuya, Hidehito Horinouchi, Takashi Seto, et al.
Pageof 22